English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Bladder cancer is a common and lethal disease. Optimal treatment for high risk patients includes local and systemic therapy (neoadjuvant or adjuvant chemotherapy). It has not been demonstrated that adjuvant chemotherapy after cystectomy prolongs survival. Evidence regarding the role of adjuvant chemotherapy is conflicting and further randomized data is needed. This publication discusses the past, present, and future of adjuvant treatment in bladder cancer. It summarizes prior adjuvant trials, with a focus on long-awaited results from a large phase III trial and the future landscape.

Adjuvant Chemotherapy for Bladder Cancer: One Step Forward, two Steps Back